18 results on '"Testani, Jeffrey M."'
Search Results
2. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
- Author
-
Pellicori, Pierpaolo, Fitchett, David, Kosiborod, Mihkail N., Ofstad, Anne P., Seman, Leo, Zinman, Bernard, Zwiener, Isabella, Wanner, Christoph, George, Jyothis, Inzucchi, Silvio E., Testani, Jeffrey M., and Cleland, John G.F.
- Abstract
Background: \ud Loop diuretics (LD) relieve symptoms and signs of congestion due to heart failure (HF), but many patients prescribed LD do not have such a diagnosis.\ud \ud Aims and methods: \ud We studied the relationship between HF diagnosis, use of LD, and outcomes in four patient subgroups with type-2 diabetes mellitus (T2DM) in EMPA-REG OUTCOME; [i) investigator-reported HF on LD, ii) investigator-reported HF not on LD, iii] no HF on LD, and iv) no HF and not on LD], and assessed their risk of CV events.\ud \ud Results: \ud Of 7,020 participants, at baseline, 706 (10%) had a diagnosis of HF, of whom 334 were prescribed LD. However, 755 (11%) patients who did not have a diagnosis of HF were prescribed LD. Compared to those with neither HF nor prescribed LD (reference group; placebo), those with both HF and receiving LD had the highest rates for all-cause (hazard ratio [HR] [95% CI]: 3.19 [2.03-5.01]) and CV mortality (3.83 [2.28-6.44]), and HF hospitalisations (HHF) (9.51 [5.61-16.14]). Patients without HF but prescribed LD had higher rates for all three outcomes (1.62 [1.10-2.39]); 1.97 [1.26-3.08]); 3.20 [1.90-5.39]), which were similar to patients with HF who were not receiving LD (1.42 [0.78-2.57]; 1.56 [0.78-3.11]; 3.00 [1.40-6.40)]). Empagliflozin had similar benefits regardless of subgroup (p for interaction >0.1 for all outcomes).\ud \ud Conclusion: \ud Patients with T2DM prescribed LD are at greater risk of CV events even if they are not reported to have HF; this might reflect under-diagnosis. Empagliflozin was similarly effective in all subgroups investigated.
- Published
- 2021
3. Early urine electrolyte patterns in patients with acute heart failure
- Author
-
Collins, Sean P., Jenkins, Cathy A., Baughman, Adrienne, Miller, Karen F., Storrow, Alan B., Han, Jin H., Brown, Nancy J., Liu, Dandan, Luther, James M., McNaughton, Candace D., Self, Wesley H., Peng, Dungeng, Testani, Jeffrey M., and Lindenfeld, JoAnn
- Subjects
Heart Failure ,Male ,Emergency department ,Sodium ,Worsening heart failure ,Acute heart failure ,Pilot Projects ,Stroke Volume ,Middle Aged ,Prognosis ,Original Research Articles ,Acute Disease ,Disease Progression ,Diuretic resistance ,Humans ,Female ,Original Research Article ,Prospective Studies ,Diuretics ,Urine electrolytes ,Biomarkers ,Aged ,Follow-Up Studies - Abstract
Aims We conducted a prospective study of emergency department (ED) patients with acute heart failure (AHF) to determine if worsening HF (WHF) could be predicted based on urinary electrolytes during the first 1–2 h of ED care. Loop diuretics are standard therapy for AHF patients. A subset of patients hospitalized for AHF will develop a blunted natriuretic response to loop diuretics, termed diuretic resistance, which often leads to WHF. Early detection of diuretic resistance could facilitate escalation of therapy and prevention of WHF. Methods and results Patients were eligible if they had an ED AHF diagnosis, had not yet received intravenous diuretics, had a systolic blood pressure > 90 mmHg, and were not on dialysis. Urine electrolytes and urine output were collected at 1, 2, 4, and 6 h after diuretic administration. Worsening HF was defined as clinically persistent or WHF requiring escalation of diuretics or administration of intravenous vasoactives after the ED stay. Of the 61 patients who qualified in this pilot study, there were 10 (16.3%) patients who fulfilled our definition of WHF. At 1 h after diuretic administration, patients who developed WHF were more likely to have low urinary sodium (9.5 vs. 43.0 mmol; P
- Published
- 2018
4. Acute Declines in Kidney Function in the Context of Decongestion in Patients with Acute Decompensated Heart Failure
- Author
-
McCallum, Wendy, Tighiouart, Hocine, Testani, Jeffrey M., Griffin, Matthew, Konstam, Marvin A., Udelson, James E., and Sarnak, Mark J.
- Subjects
Heart Failure ,Male ,Stroke Volume ,Acute Kidney Injury ,Middle Aged ,Kidney ,Prognosis ,Article ,Natriuretic Peptide, Brain ,Tolvaptan ,Humans ,Female ,Antidiuretic Hormone Receptor Antagonists ,Biomarkers ,Aged ,Glomerular Filtration Rate - Abstract
This study aimed to examine whether incorporation of a comprehensive set of measures of decongestion modifies the association of acute declines in kidney function with outcomes.In-hospital acute declines in kidney function occur in approximately 20% to 30% of patients admitted with acute decompensated heart failure (ADHF) and may be associated with adverse outcomes.Using data from EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan), we used multivariable Cox regression models to evaluate the association between in-hospital changes in estimated glomerular filtration rate (eGFR) with death and a composite outcome of cardiovascular death and hospitalization for heart failure. We evaluated eGFR declines within the context of changes in markers of volume overload including b-type natriuretic peptide (BNP), N-terminal prohormone of B-type natriuretic peptide (NT-proBNP), and weight, as well as changes in measures of hemoconcentration including hematocrit, albumin, and total protein.Among 3,715 patients over a median follow-up of 9.9 months, every 30% decline in eGFR was associated with higher risk of both death (hazard ratio [HR]: 1.19; 95% confidence interval [CI]: 1.07 to 1.31) and the composite outcome (HR: 1.09; 95% CI: 1.01 to 1.18) in adjusted models. The acute decline in eGFR was no longer associated with higher risk of either outcome as long as there was evidence of decongestion, either by declines in BNP, NT-proBNP, or weight or by increases in hematocrit, albumin or total protein. Interaction testing between decline in eGFR and changes in hematocrit, albumin, and total protein was statistically significant (p interaction of 0.01 for death and p interaction of ≤0.01 for composite for all 3 biomarkers). Interaction between change in eGFR and changes in BNP (p interaction = 0.07 for death; p interaction = 0.08 for composite), NT-proBNP (p interaction = 0.15 for death; p interaction = 0.18 for composite) and weight (p interaction = 0.13 for death; p interaction = 0.19 for composite) did not meet statistical significance.Overall, acute declines in eGFR are associated with adverse outcomes, with evidence of modification by changes in markers of decongestion, suggesting that they are no longer associated with adverse outcomes if these markers are concomitantly improving.
- Published
- 2020
5. Inflammation and Cardio-Renal Interactions in Heart Failure: A Potential Role for Interleukin-6
- Author
-
Hanberg, Jennifer S., Rao, Veena S., Ahmad, Tariq, Chunara, Zobia, Mahoney, Devin, Jackson, Keyanna, Jacoby, Daniel, Chen, Michael, Wilson, F. Perry, Tang, W. H. Wilson, Kakkar, Rahul, and Testani, Jeffrey M.
- Subjects
Heart Failure ,Inflammation ,Interleukin-6 ,Myocardium ,Humans ,Stroke Volume ,Kidney ,Article ,Glomerular Filtration Rate - Published
- 2017
6. Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research
- Author
-
Costanzo, Maria Rosa, Ronco, Claudio, Abraham, William T, Agostoni, Piergiuseppe, Barasch, Jonathan, Fonarow, Gregg C, Gottlieb, Stephen S, Jaski, Brian E, Kazory, Amir, Levin, Allison P, Levin, Howard R, Marenzi, Giancarlo, Mullens, Wilfried, Negoianu, Dan, Redfield, Margaret M, Tang, WH Wilson, Testani, Jeffrey M, and Voors, Adriaan A
- Subjects
Heart Failure ,glomerular filtration rate ,Blood Volume ,creatinine ,biomarkers ,Pilot Projects ,venous congestion ,Cardiorespiratory Medicine and Haematology ,diuretics ,Cardiovascular System & Hematology ,Public Health and Health Services ,Humans ,Hemofiltration ,Randomized Controlled Trials as Topic - Abstract
More than 1 million heart failure hospitalizations occur annually, and congestion is the predominant cause. Rehospitalizations for recurrent congestion portend poor outcomes independently of age and renal function. Persistent congestion trumps serum creatinine increases in predicting adverse heart failure outcomes. No decongestive pharmacological therapy has reduced these harmful consequences. Simplified ultrafiltration devices permit fluid removal in lower-acuity hospital settings, but with conflicting results regarding safety and efficacy. Ultrafiltration performed at fixed rates after onset of therapy-induced increased serum creatinine was not superior to standard care and resulted in more complications. In contrast, compared with diuretic agents, some data suggest that adjustment of ultrafiltration rates to patients' vital signs and renal function may be associated with more effective decongestion and fewer heart failure events. Essential aspects of ultrafiltration remain poorly defined. Further research is urgently needed, given the burden of congestion and data suggesting sustained benefits of early and adjustable ultrafiltration.
- Published
- 2017
7. Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure Current Status and Prospects for Further Research
- Author
-
Costanzo, Maria Rosa, Ronco, Claudio, Abraham, William T., Agostoni, Piergiuseppe, Barasch, Jonathan, Fonarow, Gregg C., Gottlieb, Stephen S., Jaski, Brian E., Kazory, Amir, Levin, Allison P., Levin, Howard R., Marenzi, Giancarlo, Mullens, Wilfried, Negoianu, Dan, Redfield, Margaret M., Tang, W. H. Wilson, Testani, Jeffrey M., and Voors, Adriaan A.
- Subjects
biomarkers ,creatinine ,diuretics ,glomerular filtration rate ,venous congestion - Abstract
More than 1 million heart failure hospitalizations occur annually, and congestion is the predominant cause. Rehospitalizations for recurrent congestion portend poor outcomes independently of age and renal function. Persistent congestion trumps serum creatinine increases in predicting adverse heart failure outcomes. No decongestive pharmacological therapy has reduced these harmful consequences. Simplified ultrafiltration devices permit fluid removal in lower-acuity hospital settings, but with conflicting results regarding safety and efficacy. Ultrafiltration performed at fixed rates after onset of therapy-induced increased serum creatinine was not superior to standard care and resulted in more complications. In contrast, compared with diuretic agents, some data suggest that adjustment of ultrafiltration rates to patients' vital signs and renal function may be associated with more effective decongestion and fewer heart failure events. Essential aspects of ultrafiltration remain poorly defined. Further research is urgently needed, given the burden of congestion and data suggesting sustained benefits of early and adjustable ultrafiltration. (C) 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Dr. Costanzo served as principal investigator for AVOID-HF trial; has received research support through her institution for the AVOID-HF trial; consultant for Axon Therapies. Columbia University is the assignee for biomarker patents developed by Dr. Barasch. Dr. Fonarow has received funding from National Institutes of Health; and is consultant for Amgen, Janssen, Medtronic, Novartis, and St. Jude Medical. Dr. Gottlieb has received research grants from Amgen and Novartis; and is consultant for Bristol-Myers Squibb. Dr. Levin holds equity in Coridea and Axon Therapies. Dr. Negoianu is a speaker for Gambro Inc./Baxter and Fresenius; and was a member of the Steering Committee for AVOID-HF trial. Dr. Voors has received research grants and consultancy fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Cardio3Biosciences, GlaxoSmithKline, Merck/MSD, Novartis, Servier, Sphingotec, Stealth Peptides, Trevena, and Vifor. Dr. Stough was funded by Coridea, LLC. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Published
- 2017
8. Decongestion in Acute Heart Failure Does the End Justify the Means?
- Author
-
Testani, Jeffrey M. and ter Maaten, Jozine M.
- Subjects
OUTCOMES ,LOOP DIURETICS ,acute heart failure ,REGISTRY ,TRIAL ,decongestion ,GUIDELINES ,ADHERE ,TASK-FORCE - Published
- 2016
9. Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure
- Author
-
ter Maaten, Jozine M., Rao, Veena S., Hanberg, Jennifer S., Wilson, F. Perry, Bellumkonda, Lavanya, Assefa, Mahlet, Broughton, J. Sam, D'Ambrosi, Julie, Tang, W. H. Wilson, Damman, Kevin, Voors, Adriaan A., Ellison, David H., Testani, Jeffrey M., and Cardiovascular Centre (CVC)
- Subjects
Male ,Drug Resistance ,AN ANALYSIS ,FUROSEMIDE ,Kidney ,THERAPY ,Article ,CONGESTION ,Sodium Potassium Chloride Symporter Inhibitors ,Mechanisms ,Humans ,Diuretic response ,Diuretics ,Bumetanide ,CARDIOLOGY ,Heart Failure ,Dose-Response Relationship, Drug ,NATRIURETIC RESPONSE ,Sodium ,ASSOCIATION ,Middle Aged ,EUROPEAN-SOCIETY ,Kidney Tubules ,Acute Disease ,Diuretic resistance ,Administration, Intravenous ,Female ,Biomarkers ,TASK-FORCE ,Glomerular Filtration Rate - Abstract
Background: Loop diuretic resistance is a common barrier to effective decongestion in acute heart failure (AHF), and is associated with poor outcome. Specific mechanisms underlying diuretic resistance are currently unknown in contemporary AHF patients. We therefore aimed to determine the relative importance of defects in diuretic delivery vs. renal tubular response in determining diuretic response (DR) in AHF. Methods and results: Fifty AHF patients treated with intravenous bumetanide underwent a 6-h timed urine collection for sodium and bumetanide clearance. Whole-kidney DR was defined as sodium excreted per doubling of administered loop diuretic and represents the sum of defects in drug delivery and renal tubular response. Tubular DR, defined as sodium excreted per doubling of renally cleared (urinary) loop diuretic, captures resistance specifically in the renal tubule. Median administered bumetanide dose was 3.0 (2.0-4.0) mg with 52 (33-77)% of the drug excreted into the urine. Significant between-patient variability was present as the administered dose only explained 39% of variability in the quantity of bumetanide in urine. Cumulatively, factors related to drug delivery such as renal bumetanide clearance, administered dose, and urea clearance explained 28% of the variance in whole-kidney DR. However, resistance at the level of the renal tubule (tubular DR) explained 71% of the variability in whole-kidney DR. Conclusion: Defects at the level of the renal tubule are substantially more important than reduced diuretic delivery in determining diuretic resistance in patients with AHF.
- Published
- 2016
10. The Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure: Grodin et al: Chloride Homeostasis in Heart Failure
- Author
-
Grodin, Justin L., Verbrugge, Frederik H., Ellis, Stephen G., Mullens, Wilfried, Testani, Jeffrey M., and Wilson Tang MD, W. H.
- Subjects
Heart Failure ,Male ,Time Factors ,Water-Electrolyte Imbalance ,Down-Regulation ,Kaplan-Meier Estimate ,Middle Aged ,Water-Electrolyte Balance ,Coronary Angiography ,Prognosis ,Risk Assessment ,Article ,Chlorides ,Risk Factors ,Chronic Disease ,Multivariate Analysis ,Humans ,Female ,Prospective Studies ,Biomarkers ,Aged ,Proportional Hazards Models - Abstract
The aim of this analysis was to determine the long-term prognostic value of lower serum chloride in patients with stable chronic heart failure. Electrolyte abnormalities are prevalent in patients with chronic heart failure. Little is known regarding the prognostic implications of lower serum chloride.Serum chloride was measured in 1673 consecutively consented stable patients with a history of heart failure undergoing elective diagnostic coronary angiography. All patients were followed for 5-year all-cause mortality, and survival models were adjusted for variables that confounded the chloride-risk relationship. The average chloride level was 102 ± 4 mEq/L. Over 6772 person-years of follow-up, there were 547 deaths. Lower chloride (per standard deviation decrease) was associated with a higher adjusted risk of mortality (hazard ratio 1.29, 95% confidence interval 1.12-1.49; P0.001). Chloride levels net-reclassified risk in 10.4% (P = 0.03) when added to a multivariable model (with a resultant C-statistic of 0.70), in which sodium levels were not prognostic (P = 0.30). In comparison to those with above first quartile chloride (≥ 101 mEq/L) and sodium (≥ 138 meq/L), subjects with first quartile chloride had a higher adjusted mortality risk, whether they had first quartile sodium (hazard ratio 1.35, 95% confidence interval 1.08-1.69; P = 0.008) or higher (hazard ratio 1.43, 95% confidence interval 1.12-1.85; P = 0.005). However, subjects with first quartile sodium but above first quartile chloride had no association with mortality (P = 0.67).Lower serum chloride levels are independently and incrementally associated with increased mortality risk in patients with chronic heart failure. A better understanding of the biological role of serum chloride is warranted.
- Published
- 2016
11. Amino-terminal Pro B-Type Natriuretic Peptide for Diagnosis and Prognosis in Patients with Renal Dysfunction: A Systematic Review and Meta-Analysis
- Author
-
Schaub, Jennifer A., Coca, Steven G., Moledina, Dennis G., Gentry, Mark, Testani, Jeffrey M., and Parikh, Chirag R.
- Subjects
Heart Failure ,Predictive Value of Tests ,Natriuretic Peptide, Brain ,Humans ,Kidney Failure, Chronic ,Prognosis ,Article ,Biomarkers ,Peptide Fragments ,Glomerular Filtration Rate - Abstract
This study sought to determine if amino-terminal pro-B-type natriuretic peptide (NT-proBNP) has different diagnostic and prognostic utility in patients with renal dysfunction.Patients with renal dysfunction have higher NT-proBNP, which may complicate interpretation for diagnosis of acute decompensated heart failure (ADHF) or prognosis.We searched MEDLINE and EMBASE through August 2014 for studies with a subgroup analysis by renal function of the diagnostic or prognostic ability of NT-proBNP.For diagnosis, 9 studies were included with 4,287 patients and 1,325 ADHF events. Patients were mostly divided into subgroups with and without renal dysfunction by an estimated glomerular filtration rate of 60 ml/min/1.73 m(2). In patients with renal dysfunction, the area under the curve (AUC) for NT-proBNP ranged from 0.66 to 0.89 with a median cutpoint of 1,980 pg/ml, while the AUC ranged from 0.72 to 0.95 with a cutpoint of 450 pg/ml in patients with preserved renal function. For prognosis, 30 studies with 32,203 patients were included, and mortality in patients with renal dysfunction (25.4%) was twice that of patients with preserved renal function (12.2%). The unadjusted pooled risk ratio for NT-proBNP and mortality was 3.01 (95% confidence interval [CI]: 2.53 to 3.58) in patients with preserved renal function and was similar in patients with renal dysfunction (3.25; 95% CI: 2.45 to 4.30). Upon meta-regression, heterogeneity was partially explained if patients with heart failure or coronary artery disease were enrolled.NT-proBNP retains utility for diagnosis of ADHF in patients with renal dysfunction with higher cutpoints. Elevated NT-proBNP confers a worse prognosis regardless of renal function.
- Published
- 2015
12. Substantial discrepancy between fluid and weight loss during acute decompensated heart failure treatment: Important lessons for research and clinical care
- Author
-
Testani, Jeffrey M., Brisco, Meredith A., Kociol, Robb D., Jacoby, Daniel, Bellumkonda, Lavanya, Parikh, Chirag R., Coca, Steven G., and Wilson Tang, W. H.
- Subjects
Male ,Risk Assessment ,Severity of Illness Index ,Article ,Drug Administration Schedule ,Statistics, Nonparametric ,Cohort Studies ,Sex Factors ,Double-Blind Method ,Weight Loss ,Humans ,Diuretics ,Infusions, Intravenous ,Aged ,Randomized Controlled Trials as Topic ,Aged, 80 and over ,Heart Failure ,Dose-Response Relationship, Drug ,Age Factors ,Middle Aged ,Body Fluids ,Survival Rate ,Treatment Outcome ,Acute Disease ,Female ,Follow-Up Studies - Abstract
Net fluid and weight loss are used ubiquitously to monitor diuretic response in acute decompensated heart failure research and patient care. However, the performance of these metrics has never been evaluated critically. The weight and volume of aqueous fluids such as urine should be correlated nearly perfectly and with very good agreement. As a result, significant discrepancy between fluid and weight loss during the treatment of acute decompensated heart failure would indicate measurement error in 1 or both of the parameters.The correlation and agreement (Bland-Altman method) between diuretic-induced fluid and weight loss were examined in 3 acute decompensated heart failure trials and cohorts: (1) Diuretic Optimization Strategies Evaluation (DOSE) (n = 254); (2) Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) (n = 348); and (3) Penn (n = 486).The correlation between fluid and weight loss was modest (DOSE r = 0.55; ESCAPE r = 0.48; Penn r = 0.51; P.001 for all), and the 95% limits of agreement were wide (DOSE -7.9 to 6.4 kg-L; ESCAPE -11.6 to 7.5 kg-L; Penn -14.5 to 11.3 kg-L). The median relative disagreement ranged from ±47.0% to 63.5%. A bias toward greater fluid than weight loss was found across populations (-0.74 to -2.1 kg-L, P ≤ .002). A consistent pattern of baseline characteristics or in-hospital treatment parameters that could identify patients at risk of discordant fluid and weight loss was not found.Considerable discrepancy between fluid balance and weight loss is common in patients treated for acute decompensated heart failure. Awareness of the limitations inherent to these commonly used metrics and efforts to develop more reliable measures of diuresis are critical for both patient care and research in acute decompensated heart failure.
- Published
- 2015
13. GLP-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase Mediated, Nitric Oxide Dependent Mechanisms in Conscious Dogs with Dilated Cardiomyopathy
- Author
-
Bhashyam, Siva, Fields, Anjali V., Patterson, Brandy, Testani, Jeffrey M., Chen, Li, Shen, You-tang, and Shannon, Richard P.
- Subjects
Blood Glucose ,Cardiomyopathy, Dilated ,Male ,Analysis of Variance ,Glucose Transporter Type 4 ,Consciousness ,Myocardium ,Hemodynamics ,p38 Mitogen-Activated Protein Kinases ,Article ,Glucagon-Like Peptide-1 Receptor ,Mitochondria, Heart ,Ventricular Function, Left ,Disease Models, Animal ,Random Allocation ,Dogs ,Glucagon-Like Peptide 1 ,Receptors, Glucagon ,Animals ,Female ,Nitric Oxide Synthase ,Probability ,Signal Transduction - Abstract
We have shown that glucagon-like peptide-1 (GLP-1[7-36] amide) stimulates myocardial glucose uptake in dilated cardiomyopathy (DCM) independent of an insulinotropic effect. The cellular mechanisms of GLP-1-induced myocardial glucose uptake are unknown.Myocardial substrates and glucoregulatory hormones were measured in conscious, chronically instrumented dogs at control (n=6), DCM (n=9) and DCM after treatment with a 48-hour infusion of GLP-1 (7-36) amide (n=9) or vehicle (n=6). GLP-1 receptors and cellular pathways implicated in myocardial glucose uptake were measured in sarcolemmal membranes harvested from the 4 groups. GLP-1 stimulated myocardial glucose uptake (DCM: 20+/-7 nmol/min/g; DCM+GLP-1: 61+/-12 nmol/min/g; P=0.001) independent of increased plasma insulin levels. The GLP-1 receptors were upregulated in the sarcolemmal membranes (control: 98+/-2 density units; DCM: 256+/-58 density units; P=0.046) and were expressed in their activated (65 kDa) form in DCM. The GLP-1-induced increases in myocardial glucose uptake did not involve adenylyl cyclase or Akt activation but was associated with marked increases in p38alpha MAP kinase activity (DCM+vehicle: 97+/-22 pmol ATP/mg/min; DCM+GLP-1: 170+/-36 pmol ATP/mg/min; P=0.051), induction of nitric oxide synthase 2 (DCM+vehicle: 151+/-13 density units; DCM+GLP-1: 306+/-12 density units; P=0.001), and GLUT-1 translocation (DCM+vehicle: 21+/-3% membrane bound; DCM+GLP-1: 39+/-3% membrane bound; P=0.005). The effects of GLP-1 on myocardial glucose uptake were blocked by pretreatment with the p38alpha MAP kinase inhibitor or the nonspecific nitric oxide synthase inhibitor nitro-l-arginine.GLP-1 stimulates myocardial glucose uptake through a non-Akt-1-dependent mechanism by activating cellular pathways that have been identified in mediating chronic hibernation and the late phase of ischemic preconditioning.
- Published
- 2010
14. Timing of Hemoconcentration During Treatment of Acute Decompensated Heart Failure and Subsequent Survival Importance of Sustained Decongestion
- Author
-
Testani, Jeffrey M., Brisco, Meredith A., Chen, Jennifer, McCauley, Brian D., Parikh, Chirag R., and Tang, W.H. Wilson
- Subjects
decompensated heart failure ,hemoconcentration ,mortality - Abstract
ObjectivesThis study sought to determine if the timing of hemoconcentration influences associated survival.BackgroundIndicating a reduction in intravascular volume, hemoconcentration during the treatment of decompensated heart failure has been associated with reduced mortality. However, it is unclear if this survival advantage stems from the improved intravascular volume or if healthier patients are simply more responsive to diuretics. Rapid diuresis early in the hospitalization should similarly identify diuretic responsiveness, but hemoconcentration this early would not indicate euvolemia if extravascular fluid has not yet equilibrated.MethodsConsecutive admissions at a single center with a primary discharge diagnosis of heart failure were reviewed (N = 845). Hemoconcentration was defined as an increase in both hemoglobin and hematocrit levels, then further dichotomized into early or late hemoconcentration by using the midway point of the hospitalization.ResultsHemoconcentration occurred in 422 (49.9%) patients (41.5% early and 58.5% late). Patients with late versus early hemoconcentration had similar baseline characteristics, cumulative in-hospital loop diuretic administered, and worsening of renal function. However, patients with late hemoconcentration versus early hemoconcentration had higher average daily loop diuretic doses (p = 0.001), greater weight loss (p < 0.001), later transition to oral diuretics (p = 0.03), and shorter length of stay (p < 0.001). Late hemoconcentration conferred a significant survival advantage (hazard ratio: 0.74 [95% confidence interval: 0.59 to 0.93]; p = 0.009), whereas early hemoconcentration offered no significant mortality benefit (hazard ratio: 1.0 [95% confidence interval: 0.80 to 1.3]; p = 0.93) over no hemoconcentration.ConclusionsOnly hemoconcentration occurring late in the hospitalization was associated with improved survival. These results provide further support for the importance of achieving sustained decongestion during treatment of decompensated heart failure.
- Full Text
- View/download PDF
15. Reply Hypochloremia in Acute Decompensated Heart Failure
- Author
-
Grodin, Justin L., Testani, Jeffrey M., and Tang, W.H. Wilson
- Full Text
- View/download PDF
16. Renal effects of guideline directed medical therapies in heart failure - a consensus document from the Heart Failure Association of the European Society of Cardiology
- Author
-
Wilfried Mullens, Pieter Martens, Jeffrey M. Testani, W.H. Wilson Tang, Hadi Skouri, Frederik H. Verbrugge, Marat Fudim, Massimo Iacoviello, Jennifer Franke, Andreas J. Flammer, Alberto Palazzuoli, Paola Morejon Barragan, Thomas Thum, Marta Cobo Marcos, Òscar Miró, Patrick Rossignol, Marco Metra, Johan Lassus, Francesco Orso, Ewa A. Jankowska, Ovidiu Chioncel, Davor Milicic, Loreena Hill, Petar Seferovic, Giuseppe Rosano, Andrew Coats, Kevin Damman, Clinical sciences, Cardiology, Intensive Care, Publica, Cardiovascular Centre (CVC), Verbrugge, Frederik Hendrik/0000-0003-0599-9290, Hill, Loreena/0000-0001-5232-0936, MULLENS, Wilfried, Martens, Pieter, Testani, Jeffrey M., Tang, W. H. Wilson, Skouri, Hadi, VERBRUGGE, Frederik, Fudim, Marat, Iacoviello, Massimo, Franke, Jennifer, Flammer, Andreas J., Palazzuoli, Alberto, Barragan, Paola Morejon, Thum, Thomas, Marcos, Marta Cobo, Miro, Oscar, Rossignol, Patrick, Metra, Marco, Lassus, Johan, Orso, Francesco, Jankowska, Ewa A., Chioncel, Ovidiu, Milicic, Davor, Hill, Loreena, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew, and Damman, Kevin
- Subjects
CHRONIC KIDNEY-DISEASE ,Consensus ,Left ,Cardiology ,heart failure ,Angiotensin-Converting Enzyme Inhibitors ,Heart failure ,Kidney ,GLOMERULAR-FILTRATION-RATE ,ULTRAFILTRATION ,SGLT2 INHIBITORS ,Angiotensin Receptor Antagonists ,Ventricular Dysfunction, Left ,guideline directed medical therapies ,Ventricular Dysfunction ,Humans ,Sodium-Glucose Transporter 2 Inhibitors ,Pharmacological therapy ,Renal function ,Chronic Disease ,Stroke Volume ,Heart Failure ,BLOCKER THERAPY ,IMPAIRMENT ,ANGIOTENSIN-II ,MYOCARDIAL-INFARCTION ,SURVIVAL ,renal ,Cardiology and Cardiovascular Medicine ,REDUCED EJECTION FRACTION - Abstract
Novel pharmacologic treatment options reduce mortality and morbidity in a cost-effective manner in patients with heart failure (HF). Undisputedly, the effective implementation of these agents is an essential element of good clinical practice, which is endorsed by the European Society of Cardiology (ESC) guidelines on acute and chronic HF. Yet, physicians struggle to implement these therapies as they have to balance the true and/or perceived risks versus their substantial benefits in clinical practice. Any worsening of biomarkers of renal function is often perceived as being disadvantageous and is in clinical practice one of the most common reasons for ineffective drug implementation. However, even in this context, they clearly reduce mortality and morbidity in HF with reduced ejection fraction (HFrEF) patients, even in patients with poor renal function. Furthermore these agents are also beneficial in HF with mildly reduced ejection fraction (HFmrEF) and sodium-glucose cotransporter 2 (SGLT2) inhibitors more recently demonstrated a beneficial effect in HF with preserved ejection fraction (HFpEF). The emerge of several new classes (angiotensin receptor-neprilysin inhibitor [ARNI], SGLT2 inhibitors, vericiguat, omecamtiv mecarbil) and the recommendation by the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic HF of early initiation and titration of quadruple disease-modifying therapies (ARNI/angiotensin-converting enzyme inhibitor + beta-blocker + mineralocorticoid receptor antagonist and SGLT2 inhibitor) in HFrEF increases the likelihood of treatment-induced changes in renal function. This may be (incorrectly) perceived as deleterious, resulting in inertia of starting and uptitrating these lifesaving therapies. Therefore, the objective of this consensus document is to provide advice of the effect HF drugs on renal function.
- Published
- 2022
17. Altered Hemodynamics and End-Organ Damage in Heart Failure
- Author
-
Marco Guazzi, Barry A. Borlaug, Frederik H. Verbrugge, Jeffrey M. Testani, Clinical sciences, Medicine and Pharmacy academic/administration, Cardiology, Intensive Care, Verbrugge, Frederik Hendrik/0000-0003-0599-9290, Borlaug, Barry/0000-0001-9375-0596, VERBRUGGE, Frederik, Guazzi, Marco, Testani, Jeffrey M., and Borlaug, Barry A.
- Subjects
Lung Diseases ,kidney ,lung disease ,medicine.medical_specialty ,Cardiac output ,End organ damage ,heart failure ,Hemodynamics ,Article ,lung ,Physiology (medical) ,Internal medicine ,Humans ,Medicine ,Myocytes, Cardiac ,Cardiac Output ,Lung ,Ejection fraction ,business.industry ,Cardiogenic shock ,medicine.disease ,medicine.anatomical_structure ,Nephrology ,Heart failure ,Cardiology ,Kidney Diseases ,Cardiology and Cardiovascular Medicine ,business ,Perfusion - Abstract
Heart failure is characterized by pathologic hemodynamic derangements, including elevated cardiac filling pressures ("backward" failure), which may or may not coexist with reduced cardiac output ("forward" failure). Even when normal during unstressed conditions such as rest, hemodynamics classically become abnormal during stressors such as exercise in patients with heart failure. This has important upstream and downstream effects on multiple organ systems, particularly with respect to the lungs and kidneys. Hemodynamic abnormalities in heart failure are affected by processes that extend well beyond the cardiac myocyte, including important roles for pericardial constraint, ventricular interaction, and altered venous capacity. Hemodynamic perturbations have widespread effects across multiple heart failure phenotypes, ranging from reduced to preserved ejection fraction, acute to chronic disease, and cardiogenic shock to preserved perfusion states. In the lung, hemodynamic derangements lead to the development of abnormalities in ventilatory control and efficiency, pulmonary congestion, capillary stress failure, and eventually pulmonary vascular disease. In the kidney, hemodynamic perturbations lead to sodium and water retention and worsening renal function. Improved understanding of the mechanisms by which altered hemodynamics in heart failure affect the lungs and kidneys is needed in order to design novel strategies to improve clinical outcomes. Dr Verbrugge is supported by a Fellowship of the Belgian American Educational Foundation and by the Special Research Fund of Hasselt University (grant no. BOF19PD04). Dr Borlaug is supported by grants R01 HL128526 and U01 HL125205, both from the US National Heart, Lung, and Blood Institute. Borlaug, BA (corresponding author), Mayo Clin & Mayo Fdn, 200 First St SW, Rochester, MN 55905 USA. borlaug.barry@mayo.edu
- Published
- 2020
18. Measures of Loop Diuretic Efficiency and Prognosis in Chronic Kidney Disease
- Author
-
Frederik H. Verbrugge, Pieter Martens, Dirk Kuypers, Bert Bammens, W.H. Wilson Tang, Jeffrey M. Testani, Verbrugge, Frederik Hendrik/0000-0003-0599-9290, VERBRUGGE, Frederik, MARTENS, Pieter, Testani, Jeffrey M., Tang, W. H. Wilson, Kuypers, Dirk, Bammens, Bert, Medicine and Pharmacy academic/administration, Cardiology, and Intensive Care
- Subjects
medicine.medical_specialty ,medicine.drug_class ,Urology ,medicine.medical_treatment ,Natriuresis ,Renal function ,Sodium Potassium Chloride Symporter Inhibitors ,Renal Dialysis ,medicine ,Humans ,Urine specimen collection ,Renal replacement therapy ,Mortality ,Renal Insufficiency, Chronic ,Dialysis ,Retrospective Studies ,Heart Failure ,business.industry ,Acute kidney injury ,Furosemide ,Loop diuretic ,Prognosis ,medicine.disease ,Chronic renal insufficiency ,Nephrology ,Diuretic ,Cardiology and Cardiovascular Medicine ,business ,Kidney disease ,medicine.drug - Abstract
Background: The evolution and prognostic impact of loop diuretic efficiency according to chronic kidney disease (CKD) severity is unclear. Methods: This retrospective cohort study includes 783 CKD patients on oral loop diuretic therapy with a 24-h urine collection available. Acute kidney injury and history of renal replacement therapy were exclusion criteria. Patients were stratified according to Kidney Disease Improving Global Outcomes (KDIGO) glomerular filtration rate class. Loop diuretic efficiency was calculated as urine output, natriuresis, and chloruresis, each adjusted for loop diuretic dose, and compared among strata. Risk for onset of dialysis and all-cause mortality was evaluated. Results: Loop diuretic efficiency metrics decreased from KDIGO class IIIB to IV in furosemide users and from KDIGO class IV to V with all loop diuretics (p value ρ 0.298–0.436; p value Conclusion: Low loop diuretic efficiency is independently associated with a shorter time to dialysis initiation and a higher risk for all-cause mortality in CKD.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.